British Firm Debuts Cannabis Treatment | June 28, 2010 Issue - Vol. 88 Issue 26 | Chemical & Engineering News
Volume 88 Issue 26 | p. 23 | Concentrates
Issue Date: June 28, 2010

British Firm Debuts Cannabis Treatment

Department: Business
Keywords: cannabis sativa, multiple sclerosis

GW Pharmaceuticals, in Porton Down, England, has launched Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis, in the U.K. The drug contains two cannabinoid active ingredients—THC (Δ9-tetrahydrocannabinol) and CBD (cannabidiol)—both derived from whole extracts of the Cannabis sativa plant. Bayer Schering Pharma has licensed and will distribute the drug. GW will receive a $15 million milestone payment from Bayer Schering to mark U.K. approval of the drug.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment